Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed CentralRead more →

Stage IIIB non-squamous NSCLC on chemoimmunotherapy: alcohol-related hypertonic hyponatremia corrected during oncology follow-up

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Tumor biomarkers not reported. Severe hyponatremia workup showed high serum osmolality and ethanol level.

He remained under oncology follow-up for Stage IIIB non-squamous NSCLC while alcohol-related hypertonic hyponatremia improved after detoxification and alcohol cessation.

PubMed CentralRead more →

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed CentralRead more →

Stage IIIA squamous lung cancer with pathologic complete response after immunochemotherapy

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: PD-L1 TPS 90%; PD-L1 CPS 100%; EGFR p.G719S 24.9%; EGFR p.S768I 24.6%; TP53 p.S183* 7.2%; TMB 0.0 Muts/Mb

Systematic imaging in March 2025 showed no recurrence or metastasis, with postoperative disease-free survival longer than 30 months and overall survival longer than 34 months.

PubMed CentralRead more →

Stage III Lung Cancer: Alexis's Survivor Story

Patient Info: Alexis, Female, Under 40 | Stage III

Biomarkers: No lung tumor biomarker reported

Alexis had Stage III pulmonary neuroendocrine/carcinoid cancer treated with removal of the entire left lung and 4 months of adjuvant pill chemotherapy. Follow-up scans after chemotherapy were clear, and her doctor called the status no evidence of disease; she continues long-term surveillance.

The Patient StoryRead more →

ALK-rearranged lung adenocarcinoma: sustained partial response on reduced-dose crizotinib after renal cysts

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK gene translocation positive in >15% of tumor cells by FISH

As of June 2025, the lung cancer remained in partial response without progression on reduced-dose crizotinib, while crizotinib-associated renal cysts had markedly regressed.

PubMed CentralRead more →

Stage IIIA double ALK-fusion lung adenocarcinoma: major pathological response to neoadjuvant alectinib

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK-rearranged lung adenocarcinoma with both ELMOD3-ALK and EML4-ALK fusions. CEA/NSE/CA19-9 decreased after alectinib.

As of April 2025, he had continued alectinib for 4 years after surgery, with more than 48 months of disease-free survival, no recurrence, and no serious drug-related toxicity.

PubMed CentralRead more →

Stage III Lung Squamous Cell Carcinoma Diagnosed After Months of COPD-Like Symptoms

Patient Info: Anonymized, male, 40s | Stage III

He died 6 months after his lung-cancer diagnosis from pneumonia complicated by COPD that did not respond to targeted antibiotic treatment.

PubMed CentralRead more →

Stage III Large-Cell Lung Carcinoma Found During Recurrent Pneumonia in a Woman With COPD

Patient Info: Anonymized, female, 50s | Stage III

She died 17 days after the lung-cancer diagnosis while being treated for recurrent pneumonia complicated by COPD.

PubMed CentralRead more →

Stage 3 squamous cell lung cancer: complete remission on tislelizumab monotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Squamous lung cancer markers: P40 positive, TTF-1/Napsin A negative, Ki-67 75%. PD-1/PD-L1 testing was not done.

As of April 2024, enhanced CT, tumor-marker decline, and clinical assessment supported complete remission by iRECIST after chemoimmunotherapy and tislelizumab monotherapy.

PubMed CentralRead more →

Stage III Small Cell Lung Cancer: Brian's Patient Story

Patient Info: Brian, Male | Stage III

Brian was early in treatment for Stage III limited-stage small cell lung cancer. As of February 2025, he had completed 1 round of chemotherapy, was starting concurrent radiation, and was waiting on PET scan results to assess response or spread.

The Patient StoryRead more →

Stage III small cell lung cancer with paraneoplastic optic disc swelling

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: anti-CV2/CRMP-5 positive; anti-Hu positive

Eighteen months after diagnosis, there was no evidence of cancer recurrence. Optic disc swelling had fully resolved after steroid treatment, with preserved visual function.

PubMed CentralRead more →

Stage 3 squamous cell lung cancer: major response to chemo-immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: PD-L1 30-40%

After neoadjuvant chemoimmunotherapy and sleeve right lower lobectomy, pathology showed major pathological response with negative margins, and no metastasis or recurrence was observed 6 months after surgery.

PubMed CentralRead more →

Long-Lasting Pembrolizumab Response in Stage III Lung Adenocarcinoma With STK11, TP53 and RB1 Mutations

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 and RB1 mutations; high tumor mutational burden; PD-L1 70%

Pembrolizumab produced a partial response within 3 months, improved his breathing and fatigue, and was continued for more than 2 years without significant immune-related toxicity.

PubMed CentralRead more →

ROS1-Positive Stage III Lung Adenocarcinoma With Pathologic Complete Response

Patient Info: Anonymized, male, 40s | Stage III

Biomarkers: ROS1 fusion-positive

Surgery found no residual cancer cells or involved lymph nodes, and no recurrence was detected during 10 months of crizotinib treatment and follow-up.

PubMed CentralRead more →

Stage III Large Cell Lung Cancer With Complete Response to Pembrolizumab-Based Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PD-L1 TPS >60%; no actionable gene mutations identified

Imaging showed complete response of the recurrent hilar and mediastinal lymph nodes, and he remained progression-free through 24 cycles of treatment.

PubMed CentralRead more →

Stage 3 squamous lung cancer: pathological complete response after immunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage III

Pathologic complete response after DEB-BACE plus tislelizumab followed by thoracoscopic right middle/lower lobectomy and lymph-node dissection; postoperative chemo-immunotherapy continued and reexaminations were stable.

PubMed CentralRead more →

Stage III Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi, Female | Stage III

As of November 2024, Heidi was 6 years beyond her Stage IIIA lung cancer diagnosis and active in survivorship and advocacy through The White Ribbon Project; no explicit NED status was provided.

The Patient StoryRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response to Neoadjuvant Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PIK3CA mutation; TP53 mutation; PD-L1 TPS 5%

No recurrence was detected for more than 29 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response and No Recurrence

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: NRAS mutation; TP53 mutation; PD-L1 TPS 60%

No recurrence was detected for more than 27 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma Treated With Neoadjuvant Immunochemotherapy and Surgery

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 mutation; PD-L1 TPS 40%

No recurrence was detected for more than 30 months after surgery.

PubMed CentralRead more →

Stage III EGFR exon 19-deleted lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion

No sign of metastasis on PET-CT or brain MRI after 24 months of follow-up following neoadjuvant osimertinib, left upper-lobe resection, and adjuvant osimertinib.

PubMed CentralRead more →

Stage III lung adenocarcinoma: neoadjuvant brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Specific molecular alteration not stated in case 1 raw text; treated with brigatinib

No evidence of disease on PET-CT and brain MRI 27 months after surgery while receiving adjuvant brigatinib 90 mg daily.

PubMed CentralRead more →